VIRGINIA RETIREMENT SYSTEMS ET Al Sells 56,900 Shares of Avantor, Inc. $AVTR

VIRGINIA RETIREMENT SYSTEMS ET Al decreased its position in shares of Avantor, Inc. (NYSE:AVTR) by 29.3% during the third quarter, Holdings Channel.com reports. The firm owned 137,200 shares of the company’s stock after selling 56,900 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Avantor were worth $2,065,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Sage Rhino Capital LLC lifted its stake in shares of Avantor by 17.1% in the 3rd quarter. Sage Rhino Capital LLC now owns 13,060 shares of the company’s stock valued at $197,000 after purchasing an additional 1,903 shares during the period. Simplify Asset Management Inc. acquired a new stake in Avantor during the third quarter valued at $14,537,000. Root Financial Partners LLC acquired a new stake in Avantor during the third quarter valued at $57,000. Quadrant Capital Group LLC increased its holdings in Avantor by 4.8% in the third quarter. Quadrant Capital Group LLC now owns 43,875 shares of the company’s stock valued at $682,000 after buying an additional 1,995 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Avantor by 40.8% in the third quarter. Nisa Investment Advisors LLC now owns 4,938 shares of the company’s stock valued at $74,000 after buying an additional 1,431 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Performance

NYSE AVTR opened at $15.61 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.89 and a quick ratio of 1.27. The stock’s 50 day simple moving average is $15.54 and its 200-day simple moving average is $11.27. The company has a market cap of $10.58 billion, a PE ratio of 31.22, a price-to-earnings-growth ratio of 7.06 and a beta of 0.95. Avantor, Inc. has a 1-year low of $7.26 and a 1-year high of $17.45.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.21 by $0.01. Avantor had a return on equity of 9.79% and a net margin of 5.08%. The firm had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the previous year, the business earned $0.22 earnings per share. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, equities research analysts anticipate that Avantor, Inc. will post 0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AVTR. Wall Street Zen upgraded shares of Avantor from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Royal Bank Of Canada raised their target price on Avantor from $14.00 to $17.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 28th. Evercore set a $17.00 price target on Avantor in a research note on Wednesday, October 28th. Wolfe Research raised Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Wells Fargo & Company upped their price target on Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Avantor presently has a consensus rating of “Hold” and an average target price of $14.77.

Avantor Profile

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.